Galcanezumab-Gnlm: uses, dosing, side effects & brands
Galcanezumab-Gnlm is a medicine sold in the U.S. under one brand, for cluster headache. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Cluster Headache
- Available as
- Injectable
- Sold as
- Emgality
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How galcanezumab-gnlm is dosed
From the FDA label for Emgality (application BLA761063). Other galcanezumab-gnlm products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
For subcutaneous use only. ( 2.1 , 2.2 , 2.3 ) Migraine recommended dosage: 240 mg loading dose (administered as two consecutive injections of 120 mg each), followed by monthly doses of 120 mg. ( 2.1 ) Episodic cluster headache recommended dosage: 300 mg (administered as three consecutive injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period. ( 2.2 ) Administer in the abdomen, thigh, back of the upper arm, or buttocks subcutaneously. ( 2.3 ) 2.1 Recommended Dosing for Migraine The recommended dosage of EMGALITY is 240 mg (two consecutive subcutaneous injections of 120 mg each) once as a loading dose, followed by monthly doses of 120 mg injected subcutaneously. If a dose of EMGALITY is missed, administer as soon as possible. Thereafter, EMGALITY can be scheduled monthly from the date of the last dose. 2.2 Recommended Dosing for Episodic Cluster Headache The recommended dosage of EMGALITY is 300 mg (three consecutive subcutaneous injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period. If a dose of EMGALITY is missed during a cluster period, administer as soon as possible. Thereafter, EMGALITY can be scheduled monthly from the date of the last dose until the end of the cluster period. 2.3 Important Administration Instructions EMGALITY is for subcutaneous use…
Galcanezumab-Gnlm side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] Constipation with Serious Complications [see Warnings and Precautions ( 5.2 )] Hypertension [see Warnings and Precautions ( 5.3 )] Raynaud's Phenomenon [see Warnings and Precautions ( 5.4 )] The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. Migraine The safety of EMGALITY has been evaluated in 2586 patients with migraine who received at least one dose of EMGALITY, representing 1487 patient-years of exposure. Of these, 1920 patients were exposed to EMGALITY once monthly for at least 6 months, and 526 patients were exposed for 12 months. In placebo-controlled clinical studies (Studies 1, 2, and 3), 705 patients received at least one dose of…
Who shouldn’t take galcanezumab-gnlm
EMGALITY is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients [see Warnings and Precautions ( 5.1 )] . EMGALITY is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. ( 4 )
Every galcanezumab-gnlm product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Emgality.
What people report to the FDA about galcanezumab-gnlm
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 39 reports naming galcanezumab-gnlm, and the FDA flagged 49% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- constipation5 reports
- rash5 reports
- malaise4 reports
- vomiting4 reports
- depression3 reports
- fatigue3 reports
- illness3 reports
- insomnia3 reports
Read these as a signal, not a rate. A report does not mean galcanezumab-gnlm caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is galcanezumab-gnlm?
Emgality (Galcanezumab-Gnlm) is a medication used to treat Cluster Headache.
Can you take galcanezumab-gnlm with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run galcanezumab-gnlm against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does galcanezumab-gnlm come in?
Across the brands we track, galcanezumab-gnlm is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic galcanezumab-gnlm?
We do not currently list a generic-labelled galcanezumab-gnlm product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Galcanezumab-Gnlm: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/galcanezumab-gnlm
- MLA
- “Galcanezumab-Gnlm: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/galcanezumab-gnlm.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for galcanezumab-gnlm on DailyMed (NIH) ↗.